Laura Lester

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

Eric Lawitz, Edward Gane, Brian L. Pearlman et al. · The Lancet · 2014 · 299 citations

Open-label Phase 2, Hepatology, Hepatitis C +10

Coping with sports injuries: an examination of the adolescent athlete

Janeen Manuel, Jeffrey S. Shilt, Walton W. Curl et al. · Journal of Adolescent Health · 2002 · 117 citations

Sport Rehabilitation, Kinesiology, Sport Injury Prevention +13

Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.

Robert W. Wilmott, Raouf Amin, Andrew A. Colin et al. · American Journal of Respiratory and Critical Care Medicine · 1996 · 68 citations

Asthma, Pulmonary Care, Inflammatory Lung Disease +16

Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter

Shanghong Dong, Laura Lester, Lee F. Johnson · Journal of Cellular Biochemistry · 2000 · 54 citations

Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population.

Laura Lester, Jerome R. Kraut, John D. Lloyd‐Still et al. · PubMed · 1994 · 50 citations